MedTrace Logo

Clinical Study of Multiple Dose Genakumab for Injection in Chinese Healthy Adults

NCT05894148 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-04-01

No results posted yet for this study

Summary

To evaluate the safety and tolerability of multiple-dose subcutaneous injections of Genakumab for Injection in Chinese healthy adult volunteers.

Conditions

Interventions

DRUG

Genakumab injection

Group 1: 120mg Q4W，group 2: 200mg Q4W

DRUG

placebo

The placebo contains other excipients except Genakumab, and its appearance is consistent with that of Genakumab for injection.

Sponsors & Collaborators

  • Affiliated Hospital of North Sichuan Medical College

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaolan Yong, bachelor · Chengdu Xinhua Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2023-11-30
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05894148 on ClinicalTrials.gov